

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CLARITY MEDICAL GROUP HOLDING LIMITED**

**清晰醫療集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

### **(1) QUARTERLY UPDATE ON BUSINESS OPERATIONS AND RESUMPTION STATUS; AND (2) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Clarity Medical Group Holding Limited (the “**Company**”, which together with its subsidiaries are collectively referred to the “**Group**”) pursuant to Rules 13.09(2) (a) and 13.24A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Future Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated 30 May 2025 in relation to the resumption guidance issued by the Stock Exchange (the “**First Resumption Guidance**”), (ii) the announcement of the Company dated 30 June 2025 in relation to the additional resumption guidance given by the Stock Exchange (together with the First Resumption Guidance, the “**Resumption Guidance**”); and (iii) the announcement of the Company dated 14 July 2025 providing quarterly update on its business operations and resumption status. Unless otherwise stated, capitalised terms used in this announcement shall have the same meanings as those defined in the above-mentioned announcements.

Unless otherwise stated, all references to Rules and Chapters in this announcement are references to the rules and chapters of the Listing Rules.

Pursuant to Rule 13.24A, an update on the business operations of the Group and the current status of fulfilment of the Resumption Guidance is set out below.

## **BUSINESS OPERATIONS**

The Group continues to provide high quality ophthalmic healthcare services for the six months from 31 March 2025 to 30 September 2025 (“**FY2026 Half Year**”).

### **Business Update for FY2026 Half Year**

The Group recorded revenue of approximately HK\$85 million for FY2026 Half Year, representing a slight decrease of less than 3% compared to the same period last year. The Group’s Hong Kong clinics were closed or significantly disrupted for eight days between July and September due to extreme adverse weather conditions. In addition, negative media coverage arising from allegations made by a former Director have adversely affected the Group’s business operations in recent months.

The Company further strengthened its technology leadership in Hong Kong’s ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce its next-generation refractive surgery procedure, SILK™, which utilizes low-energy, ultra-precise femtosecond laser pulses that minimize corneal tissue disruption and nerve damage, enabling faster recovery and superior visual outcomes. As the first and only provider in Hong Kong to offer the SILK™ procedure, the Company plans to introduce it in the fourth quarter of 2025.

As mentioned in the Company’s quarterly update announcement dated 14 July 2025, the ongoing allegations concerning the Company have hindered the execution of key strategic initiatives and impaired business operations. The Group remains committed to bringing the investigation to a close efficiently and stabilizing operations, allowing management to refocus on advancing long-term strategic priorities.

Save as disclosed above, the business operations of the Group are continuing as usual in all material respects, notwithstanding that trading in the shares of the Company has been suspended since 15 April 2025.

## **RESUMPTION GUIDANCE**

The latest Resumption Guidance for the Company as at the date of this announcement is as follows:

- (i) the Allegations Investigation and Remedial Guidance;
- (ii) the Integrity Guidance;
- (iii) the Internal Control Guidance;
- (iv) the Corporate Governance Guidance;
- (v) the Disclosure Guidance;
- (vi) the Financial Reporting Guidance; and
- (vii) the Rule 13.24 Guidance.

## **RESUMPTION STATUS**

The current status of fulfilment of the Resumption Guidance as at the date of this announcement is summarised below:

### ***Allegations Investigation and Remedial Guidance***

As disclosed in the announcement of the Company dated 13 May 2025, the Company held a Board meeting on 18 February 2025 and resolved that Ms. Cheng Jessica (“**Ms. Cheng**”) and Mr. Wang Can (“**Mr. Wang**”) will both remain as members of the Special Committee. The Board also announced that on 26 March 2025, the Special Committee appointed PricewaterhouseCoopers Consulting Hong Kong Limited to act as the forensic adviser to the Special Committee. As at the date of this announcement, the Company is still in the process of conducting forensic investigations into the above matters. Further announcement(s) will be made by the Company as to the findings of the forensic investigation results and the appropriate remedial actions taken.

As disclosed in the announcement of the Company dated 3 July 2025, the Company has established the Separate Special Committee, which comprises of Mr. Lee Kam Hung Lawrence, BBS, JP (as the chairman and as an external independent legal expert), Ms. Cheng, Mr. Wang and Ms. Ci Ying. The Separate Special Committee has finalised its terms of reference pursuant to which the purpose of that committee is to investigate the allegations in respect of the Company’s initial public offer (“**IPO**”) and disclosures in its IPO prospectus. The Separate Special Committee has appointed BDO Financial Services Limited to act as the forensic adviser to the Separate Special Committee. As at the date of this announcement, the Company is still in the process of conducting the investigations. Further announcement(s) will be made by the Company as to the findings of the investigation results.

### ***Integrity Guidance***

The Company will gather and provide the Stock Exchange with all required details and justifications to demonstrate compliance with the Integrity Guidance.

### ***Internal Control Guidance***

As at the date of this announcement, the Company is still in the process of appointing a suitable independent internal control adviser to conduct the independent internal control review.

Further announcement(s) will be made by the Company as to any significant findings of the internal control review including, where necessary, any recommendation of reinforcement or remedial actions and their implementation status in due course.

### ***Corporate Governance Guidance***

As disclosed in the announcement of the Company dated 1 September 2025, the Company has re-complied with Rule 3.25, as required by the Resumption Guidance.

The Company has not yet re-complied with Rule 3.21 in respect of the composition of the Audit Committee. The Company will identify suitable independent non-executive Director candidate to fill up the vacancy of the Audit Committee. Further announcement(s) will be made in this regard as and when appropriate in accordance with the requirements of the Listing Rules.

### ***Disclosure Guidance***

The Company has complied with and will continue to comply with the Disclosure Guidance promptly as needed.

## ***Financial Reporting Guidance***

As disclosed in the announcement of the Company dated 25 June 2025 in relation to the delay in publication of the FY2025 Audited Annual Results and despatch of the FY2025 Annual Report, the Company is still in the process of addressing the Allegations which are considered by the Auditor as relevant to the FY2025 Audited Annual Results. The Auditor still considers that there are material uncertainties on the impacts to the Company's financial information before such Allegations have been sufficiently investigated into. As such, there has been a delay in publication of the FY2025 Audited Annual Results and in despatch of the FY2025 Annual Report.

The Board has assessed again that the delay in announcing the FY2025 Audited Annual Results and in despatching the FY2025 Annual Report would not have any material adverse effect to the Group's business and operation, which are continuing normally.

The Board is of the view that the expected date of the publication of the FY2025 Audited Annual Results and the FY2025 Annual Report will need to be further determined with the Auditor. The Company will publish further announcement(s) to inform its shareholders and potential investors of the developments relating to the publication of the FY2025 Audited Annual Results and the FY2025 Annual Report as and when appropriate.

## ***Rule 13.24 Guidance***

The Group has all along been in compliance with Rule 13.24, in particular, given the Group's substantive business operations, as well as proactive cost-saving initiatives in reducing operating expenses without compromising the quality of its services. The Company will gather and provide the Stock Exchange with all required details and justifications to demonstrate compliance with the Rule 13.24 Guidance.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the shares or other securities of the Company, and if they are in any doubt about their position, they should consult their independent professional adviser(s).**

By order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 14 October 2025

*As at the date of this announcement, the Board comprises Mr. JIANG Bo and Mr. HUI Yung Chris as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Mr. CHEN Jiarong as non-executive Director, and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.*